{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-023387","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2026-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.769754+00:00","generated_at":"2026-05-16T07:33:05.215831+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA lifts clinical hold on Intellia's MAGNITUDE-2 Phase 3 trial for ATTRv-PN; MAGNITUDE hold ongoing","bullets":["FDA removed clinical hold on IND for MAGNITUDE-2 Phase 3 trial of nex-z for ATTRv-PN, imposed Oct 29, 2025 after Grade 4 liver event and patient death.","Intellia to resume patient enrollment with enhanced liver safety monitoring; target enrollment increased from ~50 to ~60 patients.","FDA engagement ongoing for clinical hold on MAGNITUDE Phase 3 trial for ATTR-CM; no update on path forward yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-023387","json":"https://secwatch.observer/filing/0001193125-26-023387.json","markdown":"https://secwatch.observer/filing/0001193125-26-023387.md","text":"https://secwatch.observer/filing/0001193125-26-023387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526023387/0001193125-26-023387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526023387/d29201d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:33:05.215831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}